{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:15:39Z","timestamp":1789906539429,"version":"4.0.1"},"reference-count":111,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002261","name":"\u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u0438\u0439 \u0424\u043e\u043d\u0434 \u0424\u0443\u043d\u0434\u0430\u043c\u0435\u043d\u0442\u0430\u043b\u044c\u043d\u044b\u0445 \u0418\u0441\u0441\u043b\u0435\u0434\u043e\u0432\u0430\u043d\u0438\u0439","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002261","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.drudis.2019.03.013","type":"journal-article","created":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T04:03:20Z","timestamp":1552622600000},"page":"1139-1147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["New targets for HIV drug discovery"],"prefix":"10.1016","volume":"24","author":[{"given":"Ana C.","family":"Puhl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Garzino Demo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadim A.","family":"Makarov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Ekins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2019.03.013_bib0005","doi-asserted-by":"crossref","first-page":"a006841","DOI":"10.1101\/cshperspect.a006841","article-title":"Origins of HIV and the AIDS pandemic","volume":"1","author":"Sharp","year":"2011","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.drudis.2019.03.013_bib0010","unstructured":"WHO. (2018) HIV\/AIDS."},{"key":"10.1016\/j.drudis.2019.03.013_bib0015","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.drudis.2014.05.012","article-title":"An analysis of FDA-approved drugs for infectious disease: HIV\/AIDS drugs","volume":"19","author":"Kinch","year":"2014","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.drudis.2019.03.013_bib0020","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2165\/11597770-000000000-00000","article-title":"HIV-associated neurological disorders: a guide to pharmacotherapy","volume":"26","author":"Tan","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.drudis.2019.03.013_bib0025","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/s11481-013-9513-1","article-title":"More than two HANDs to tango","volume":"8","author":"Kolson","year":"2013","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/j.drudis.2019.03.013_bib0030","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.neuron.2009.09.042","article-title":"A coat of many colors: neuroimmune crosstalk in human immunodeficiency virus infection","volume":"64","author":"Kraft-Terry","year":"2009","journal-title":"Neuron"},{"key":"10.1016\/j.drudis.2019.03.013_bib0035","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.2174\/1381612822666160726113001","article-title":"Solving the blood\u2013brain barrier challenge for the effective treatment of HIV replication in the central nervous system","volume":"22","author":"Bertrand","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.drudis.2019.03.013_bib0040","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2217\/17469600.2.3.271","article-title":"Developing neuroprotective strategies for treatment of HIV-associated neurocognitive dysfunction","volume":"2","author":"Rumbaugh","year":"2008","journal-title":"Future HIV Ther."},{"key":"10.1016\/j.drudis.2019.03.013_bib0045","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nrneurol.2016.53","article-title":"HIV-associated neurocognitive disorder \u2013 pathogenesis and prospects for treatment","volume":"12","author":"Saylor","year":"2016","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.drudis.2019.03.013_bib0050","doi-asserted-by":"crossref","first-page":"586401","DOI":"10.1155\/2012\/586401","article-title":"HIV-1 reverse transcriptase still remains a new drug target: structure, function, classical inhibitors, and new inhibitors with innovative mechanisms of actions","volume":"2012","author":"Esposito","year":"2012","journal-title":"Mol. Biol. Int."},{"key":"10.1016\/j.drudis.2019.03.013_bib0055","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.virusres.2011.08.001","article-title":"Host factors mediating HIV-1 replication","volume":"161","author":"Friedrich","year":"2011","journal-title":"Virus Res."},{"key":"10.1016\/j.drudis.2019.03.013_bib0060","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJMoa0802905","article-title":"Long-term control of HIV by CCR5 Delta32\/Delta32 stem-cell transplantation","volume":"360","author":"Hutter","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2019.03.013_bib0065","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJMoa1300662","article-title":"Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV","volume":"370","author":"Tebas","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2019.03.013_bib0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/viro.1998.9098","article-title":"Cellular factors in the transcription and replication of viral RNA genomes: a parallel to DNA-dependent RNA transcription","volume":"244","author":"Lai","year":"1998","journal-title":"Virology"},{"key":"10.1016\/j.drudis.2019.03.013_bib0075","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.tcb.2014.06.002","article-title":"Legionella pneumophila type IV effectors hijack the transcription and translation machinery of the host cell","volume":"24","author":"Rolando","year":"2014","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.drudis.2019.03.013_bib0080","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/ng.3741","article-title":"A genome-wide CRISPR screen identifies a restricted set of HIV host dependency factors","volume":"49","author":"Park","year":"2017","journal-title":"Nat. Genet."},{"key":"10.1016\/j.drudis.2019.03.013_bib0085","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0092-8674(00)80577-2","article-title":"Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry","volume":"96","author":"Farzan","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2019.03.013_bib0090","doi-asserted-by":"crossref","first-page":"17645","DOI":"10.1074\/jbc.M111.325498","article-title":"3\u2032-Phosphoadenosine 5\u2032-phosphosulfate (PAPS) synthases, naturally fragile enzymes specifically stabilized by nucleotide binding","volume":"287","author":"van den Boom","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2019.03.013_bib0095","doi-asserted-by":"crossref","first-page":"25958","DOI":"10.1074\/jbc.M302439200","article-title":"Molecular cloning and identification of 3\u2032-phosphoadenosine 5\u2032-phosphosulfate transporter","volume":"278","author":"Kamiyama","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2019.03.013_bib0100","doi-asserted-by":"crossref","first-page":"11031","DOI":"10.1073\/pnas.172380899","article-title":"Tyrosine sulfation of CCR5 N-terminal peptide by tyrosylprotein sulfotransferases 1 and 2 follows a discrete pattern and temporal sequence","volume":"99","author":"Seibert","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2019.03.013_bib0105","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1100\/tsw.2009.52","article-title":"Biophysical and structural studies on the capsid protein of the human immunodeficiency virus type 1: a new drug target?","volume":"9","author":"Neira","year":"2009","journal-title":"ScientificWorldJournal"},{"key":"10.1016\/j.drudis.2019.03.013_bib0110","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/2211068213513453","article-title":"Development of a novel screening strategy designed to discover a new class of HIV drugs","volume":"19","author":"Cheng","year":"2014","journal-title":"J. Lab. Autom."},{"key":"10.1016\/j.drudis.2019.03.013_bib0115","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00894-012-1560-7","article-title":"Discovery of novel low-molecular-weight HIV-1 inhibitors interacting with cyclophilin A using in silico screening and biological evaluations","volume":"19","author":"Tian","year":"2013","journal-title":"J. Mol. Model."},{"key":"10.1016\/j.drudis.2019.03.013_bib0120","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1128\/AAC.00152-07","article-title":"Phase I and II study of the safety, virologic effect, and pharmacokinetics\/pharmacodynamics of single-dose 3-o-(3\u2032,3\u2032-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection","volume":"51","author":"Smith","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drudis.2019.03.013_bib0125","first-page":"e02155","article-title":"Inhibition of HIV-1 maturation via small-molecule targeting of the amino-terminal domain in the viral capsid protein","volume":"91","author":"Wang","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.drudis.2019.03.013_bib0130","doi-asserted-by":"crossref","first-page":"6643","DOI":"10.1128\/JVI.00493-12","article-title":"Distinct effects of two HIV-1 capsid assembly inhibitor families that bind the same site within the N-terminal domain of the viral CA protein","volume":"86","author":"Lemke","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.drudis.2019.03.013_bib0135","doi-asserted-by":"crossref","first-page":"12800","DOI":"10.1128\/JVI.78.23.12800-12808.2004","article-title":"Target cell cyclophilin A modulates human immunodeficiency virus type 1 infectivity","volume":"78","author":"Sokolskaja","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.drudis.2019.03.013_bib0140","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1016\/j.bmc.2009.02.051","article-title":"Discovery of dual inhibitors targeting both HIV-1 capsid and human cyclophilin A to inhibit the assembly and uncoating of the viral capsid","volume":"17","author":"Li","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.drudis.2019.03.013_bib0145","doi-asserted-by":"crossref","first-page":"10714","DOI":"10.1038\/ncomms10714","article-title":"Cyclophilin A stabilizes the HIV-1 capsid through a novel non-canonical binding site","volume":"7","author":"Liu","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drudis.2019.03.013_bib0150","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/0092-8674(89)90043-3","article-title":"Protein disulfide isomerase: multiple roles in the modification of nascent secretory proteins","volume":"57","author":"Freedman","year":"1989","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2019.03.013_bib0155","doi-asserted-by":"crossref","first-page":"50579","DOI":"10.1074\/jbc.M204547200","article-title":"Inhibitors of protein-disulfide isomerase prevent cleavage of disulfide bonds in receptor-bound glycoprotein 120 and prevent HIV-1 entry","volume":"277","author":"Gallina","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2019.03.013_bib0160","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1074\/jbc.M205467200","article-title":"Protein-disulfide isomerase-mediated reduction of two disulfide bonds of HIV envelope glycoprotein 120 occurs post-CXCR4 binding and is required for fusion","volume":"278","author":"Barbouche","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2019.03.013_bib0165","doi-asserted-by":"crossref","first-page":"13967","DOI":"10.1016\/S0021-9258(18)71626-8","article-title":"Selective inhibition of protein disulfide isomerase by estrogens","volume":"264","author":"Tsibris","year":"1989","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2019.03.013_bib0170","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1021\/cb100387r","article-title":"Discovery of a small molecule PDI inhibitor that inhibits reduction of HIV-1 envelope glycoprotein gp120","volume":"6","author":"Khan","year":"2011","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.drudis.2019.03.013_bib0175","doi-asserted-by":"crossref","first-page":"10650","DOI":"10.1073\/pnas.1017954108","article-title":"Galectin-9 binding to cell surface protein disulfide isomerase regulates the redox environment to enhance T-cell migration and HIV entry","volume":"108","author":"Bi","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2019.03.013_bib0180","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1016\/j.bmc.2016.09.057","article-title":"Design, synthesis and evaluation of small molecule CD4-mimics as entry inhibitors possessing broad spectrum anti-HIV-1 activity","volume":"24","author":"Curreli","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.drudis.2019.03.013_bib0185","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1021\/acsmedchemlett.5b00471","article-title":"Small-molecule CD4-mimics: structure-based optimization of HIV-1 entry inhibition","volume":"7","author":"Melillo","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.drudis.2019.03.013_bib0190","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2217\/fvl.13.6","article-title":"Role of cellular iron and oxygen in the regulation of HIV-1 infection","volume":"8","author":"Nekhai","year":"2013","journal-title":"Future Virol."},{"key":"10.1016\/j.drudis.2019.03.013_bib0195","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1007\/s11262-018-1589-5","article-title":"Lysine-specific demethylase 1 cooperates with BRAF-histone deacetylase complex 80 to enhance HIV-1 Tat-mediated transactivation","volume":"54","author":"Liu","year":"2018","journal-title":"Virus Genes"},{"key":"10.1016\/j.drudis.2019.03.013_bib0200","doi-asserted-by":"crossref","first-page":"4122","DOI":"10.2174\/1381612823666170704123620","article-title":"Protein phosphatase-1-targeted small molecules, iron chelators and curcumin analogs as HIV-1 antivirals","volume":"23","author":"Lin","year":"2017","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.drudis.2019.03.013_bib0205","doi-asserted-by":"crossref","first-page":"e02203","DOI":"10.1128\/JVI.02203-17","article-title":"Developing and evaluating inhibitors against the RNase H active site of HIV-1 reverse transcriptase","volume":"92","author":"Boyer","year":"2018","journal-title":"J. Virol."},{"key":"10.1016\/j.drudis.2019.03.013_bib0210","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1021\/jm501799k","article-title":"Structure-activity relationship of pyrrolyl diketo acid derivatives as dual inhibitors of HIV-1 integrase and reverse transcriptase ribonuclease H domain","volume":"58","author":"Cuzzucoli Crucitti","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2019.03.013_bib0215","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1093\/femspd\/ftx078","article-title":"Design, synthesis and antiviral evaluation of novel heteroarylcarbothioamide derivatives as dual inhibitors of HIV-1 reverse transcriptase-associated RNase H and RDDP functions","volume":"75","author":"Corona","year":"2017","journal-title":"Pathog. Dis."},{"key":"10.1016\/j.drudis.2019.03.013_bib0220","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ddtec.2017.11.002","article-title":"Protein\u2013protein and protein\u2013chromatin interactions of LEDGF\/p75 as novel drug targets","volume":"24","author":"Blokken","year":"2017","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.drudis.2019.03.013_bib0225","first-page":"31","article-title":"Tyrosine kinases as essential cellular cofactors and potential therapeutic targets for human immunodeficiency virus infection","volume":"58","author":"Bertoletti","year":"2012","journal-title":"Cell Mol. Biol."},{"key":"10.1016\/j.drudis.2019.03.013_bib0230","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1097\/00002030-199609000-00003","article-title":"HIV infection in vitro enhances the activity of Src-family protein tyrosine kinases","volume":"10","author":"Phipps","year":"1996","journal-title":"AIDS"},{"key":"10.1016\/j.drudis.2019.03.013_bib0235","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1097\/QAD.0000000000001028","article-title":"c-SRC protein tyrosine kinase regulates early HIV-1 infection post-entry","volume":"30","author":"McCarthy","year":"2016","journal-title":"AIDS"},{"key":"10.1016\/j.drudis.2019.03.013_bib0240","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cytogfr.2014.11.010","article-title":"Nef, the shuttling molecular adaptor of HIV, influences the cytokine network","volume":"26","author":"Percario","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.drudis.2019.03.013_bib0245","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cytogfr.2018.02.005","article-title":"Multilayered and versatile inhibition of cellular antiviral factors by HIV and SIV accessory proteins","volume":"40","author":"Sauter","year":"2018","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.drudis.2019.03.013_bib0250","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/tra.12412","article-title":"HIV-1 Nef: taking control of protein trafficking","volume":"17","author":"Pereira","year":"2016","journal-title":"Traffic"},{"key":"10.1016\/j.drudis.2019.03.013_bib0255","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1101\/gad.3.4.547","article-title":"Structure, sequence, and position of the stem-loop in tar determine transcriptional elongation by tat through the HIV-1 long terminal repeat","volume":"3","author":"Selby","year":"1989","journal-title":"Genes Dev."},{"key":"10.1016\/j.drudis.2019.03.013_bib0260","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(13)61809-7","article-title":"The end of AIDS: HIV infection as a chronic disease","volume":"382","author":"Deeks","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2019.03.013_bib0265","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.cell.2015.02.009","article-title":"A hardwired HIV latency program","volume":"160","author":"Razooky","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2019.03.013_bib0270","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/COH.0b013e328340ffbb","article-title":"The molecular biology of HIV latency: breaking and restoring the Tat-dependent transcriptional circuit","volume":"6","author":"Karn","year":"2011","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.drudis.2019.03.013_bib0275","doi-asserted-by":"crossref","first-page":"11336","DOI":"10.1128\/JVI.75.23.11336-11343.2001","article-title":"Induction of TAK (cyclin T1\/P-TEFb) in purified resting CD4(+) T lymphocytes by combination of cytokines","volume":"75","author":"Ghose","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.drudis.2019.03.013_bib0280","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0092-8674(00)81630-X","article-title":"Host control of HIV-1 parasitism in T cells by the nuclear factor of activated T cells","volume":"95","author":"Kinoshita","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2019.03.013_bib0285","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/326711a0","article-title":"An inducible transcription factor activates expression of human immunodeficiency virus in T cells","volume":"326","author":"Nabel","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2019.03.013_bib0290","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.1038\/sj.emboj.7601928","article-title":"CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency","volume":"26","author":"Tyagi","year":"2007","journal-title":"EMBO J."},{"key":"10.1016\/j.drudis.2019.03.013_bib0295","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1128\/MCB.22.9.2965-2973.2002","article-title":"Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 (HIV-1) by the HIV-1 repressor YY1 and HIV-1 activator Tat","volume":"22","author":"He","year":"2002","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.drudis.2019.03.013_bib0300","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.chom.2008.05.016","article-title":"Transcriptional interference antagonizes proviral gene expression to promote HIV latency","volume":"4","author":"Lenasi","year":"2008","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.drudis.2019.03.013_bib0305","doi-asserted-by":"crossref","first-page":"8925","DOI":"10.1073\/pnas.90.19.8925","article-title":"Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication","volume":"90","author":"Gao","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2019.03.013_bib0310","doi-asserted-by":"crossref","first-page":"19960","DOI":"10.1074\/jbc.M603336200","article-title":"The SWI\/SNF chromatin-remodeling complex is a cofactor for Tat transactivation of the HIV promoter","volume":"281","author":"Mahmoudi","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2019.03.013_bib0315","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1038\/sj.emboj.7601074","article-title":"Requirement for SWI\/SNF chromatin-remodeling complex in Tat-mediated activation of the HIV-1 promoter","volume":"25","author":"Treand","year":"2006","journal-title":"EMBO J."},{"key":"10.1016\/j.drudis.2019.03.013_bib0320","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1742-4690-10-67","article-title":"HIV-1 transcription and latency: an update","volume":"10","author":"Van Lint","year":"2013","journal-title":"Retrovirology"},{"key":"10.1016\/j.drudis.2019.03.013_bib0325","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1172\/JCI80565","article-title":"Molecular mechanisms of HIV latency","volume":"126","author":"Cary","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.drudis.2019.03.013_bib0330","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.virol.2009.01.013","article-title":"Latently-infected CD4+ T cells are enriched for HIV-1 Tat variants with impaired transactivation activity","volume":"387","author":"Yukl","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.drudis.2019.03.013_bib0335","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00465-15","article-title":"The Tat inhibitor didehydro-cortistatin A prevents HIV-1 reactivation from latency","volume":"6","author":"Mousseau","year":"2015","journal-title":"MBio"},{"key":"10.1016\/j.drudis.2019.03.013_bib0340","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.celrep.2017.09.080","article-title":"In vivo suppression of HIV rebound by didehydro-cortistatin A, a \u201cblock-and-lock\u201d strategy for HIV-1 treatment","volume":"21","author":"Kessing","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.drudis.2019.03.013_bib0345","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0067873","article-title":"Dendritic cell immunoreceptor is a new target for anti-AIDS drug development: identification of DCIR\/HIV-1 inhibitors","volume":"8","author":"Lambert","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2019.03.013_bib0350","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.chom.2016.11.001","article-title":"The mTOR complex controls HIV latency","volume":"20","author":"Besnard","year":"2016","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.drudis.2019.03.013_bib0355","doi-asserted-by":"crossref","first-page":"20476","DOI":"10.1073\/pnas.0810843106","article-title":"Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1","volume":"105","author":"Heredia","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2019.03.013_bib0360","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1128\/AAC.02496-13","article-title":"Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro","volume":"58","author":"Gavegnano","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drudis.2019.03.013_bib0365","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006740","article-title":"Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors","volume":"13","author":"Gavegnano","year":"2017","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.drudis.2019.03.013_bib0370","doi-asserted-by":"crossref","first-page":"17722","DOI":"10.1074\/jbc.M110.184739","article-title":"Host protein Ku70 binds and protects HIV-1 integrase from proteasomal degradation and is required for HIV replication","volume":"286","author":"Zheng","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2019.03.013_bib0375","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.0030041","article-title":"SIRT1 regulates HIV transcription via Tat deacetylation","volume":"3","author":"Pagans","year":"2005","journal-title":"PLoS Biol."},{"key":"10.1016\/j.drudis.2019.03.013_bib0380","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.chom.2008.02.002","article-title":"Human immunodeficiency virus type 1 Tat protein inhibits the SIRT1 deacetylase and induces T cell hyperactivation","volume":"3","author":"Kwon","year":"2008","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.drudis.2019.03.013_bib0385","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/nrm2249","article-title":"AMP-activated\/SNF1 protein kinases: conserved guardians of cellular energy","volume":"8","author":"Hardie","year":"2007","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.drudis.2019.03.013_bib0390","doi-asserted-by":"crossref","first-page":"478","DOI":"10.2174\/138920308785915254","article-title":"AMP-activated protein kinase: structure and regulation","volume":"9","author":"Sanz","year":"2008","journal-title":"Curr. Protein Pept. Sci."},{"key":"10.1016\/j.drudis.2019.03.013_bib0395","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.virusres.2009.08.005","article-title":"SIRT1 regulates Tat-induced HIV-1 transactivation through activating AMP-activated protein kinase","volume":"146","author":"Zhang","year":"2009","journal-title":"Virus Res."},{"key":"10.1016\/j.drudis.2019.03.013_bib0400","doi-asserted-by":"crossref","first-page":"e02230","DOI":"10.1128\/JVI.02230-16","article-title":"Mechanism of enhanced HIV restriction by virion coencapsidated cytidine deaminases APOBEC3F and APOBEC3G","volume":"91","author":"Ara","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.drudis.2019.03.013_bib0405","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2174\/138955708783744047","article-title":"Cytidine deaminases as a weapon against retroviruses and a new target for antiviral therapy","volume":"8","author":"Izumi","year":"2008","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.drudis.2019.03.013_bib0410","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1182\/blood-2009-06-226423","article-title":"CCR6 ligands inhibit HIV by inducing APOBEC3G","volume":"115","author":"Lafferty","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2019.03.013_bib0415","doi-asserted-by":"crossref","DOI":"10.3390\/v9050111","article-title":"Human beta defensin 2 selectively inhibits HIV-1 in highly permissive CCR6(+)CD4(+) T cells","volume":"9","author":"Lafferty","year":"2017","journal-title":"Viruses"},{"key":"10.1016\/j.drudis.2019.03.013_bib0420","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1016\/j.bmc.2018.04.059","article-title":"Synthesis and structure-activity relationship studies of MI-2 analogues as MALT1 inhibitors","volume":"26","author":"Wu","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.drudis.2019.03.013_bib0425","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/j.bmcl.2018.05.017","article-title":"N-aryl-piperidine-4-carboxamides as a novel class of potent inhibitors of MALT1 proteolytic activity","volume":"28","author":"Schlapbach","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.drudis.2019.03.013_bib0430","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1089\/aid.2015.0343","article-title":"Short communication: preferential killing of HIV latently infected CD4(+) T cells by MALT1 inhibitor","volume":"32","author":"Li","year":"2016","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.drudis.2019.03.013_bib0435","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1152\/advan.00058.2013","article-title":"Pattern recognition receptors in innate immunity, host defense, and immunopathology","volume":"37","author":"Suresh","year":"2013","journal-title":"Adv. Physiol. Educ."},{"key":"10.1016\/j.drudis.2019.03.013_bib0440","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/ni.3157","article-title":"Innate immunity against HIV-1 infection","volume":"16","author":"Altfeld","year":"2015","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.drudis.2019.03.013_bib0445","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002937","article-title":"A role for microRNA-155 modulation in the anti-HIV-1 effects of Toll-like receptor 3 stimulation in macrophages","volume":"8","author":"Swaminathan","year":"2012","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.drudis.2019.03.013_bib0450","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1084\/jem.185.5.805","article-title":"C-C chemokines released by lipopolysaccharide (LPS)-stimulated human macrophages suppress HIV-1 infection in both macrophages and T cells","volume":"185","author":"Verani","year":"1997","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.drudis.2019.03.013_bib0455","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1126\/science.270.5243.1811","article-title":"Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells","volume":"270","author":"Cocchi","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.drudis.2019.03.013_bib0460","doi-asserted-by":"crossref","first-page":"PL383","DOI":"10.1016\/S0024-3205(97)00294-4","article-title":"Polysaccharopeptide from Coriolus versicolor has potential for use against human immunodeficiency virus type 1 infection","volume":"60","author":"Collins","year":"1997","journal-title":"Life Sci."},{"key":"10.1016\/j.drudis.2019.03.013_bib0465","doi-asserted-by":"crossref","first-page":"8741698","DOI":"10.1155\/2018\/8741698","article-title":"Naturally derived anti-HIV polysaccharide peptide (PSP) triggers a Toll-like receptor 4-dependent antiviral immune response","volume":"2018","author":"Rodriguez-Valentin","year":"2018","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.drudis.2019.03.013_bib0470","doi-asserted-by":"crossref","first-page":"11086","DOI":"10.1128\/JVI.00453-12","article-title":"YB-1 functions as a porter to lead influenza virus ribonucleoprotein complexes to microtubules","volume":"86","author":"Kawaguchi","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.drudis.2019.03.013_bib0475","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1099\/0022-1317-80-10-2629","article-title":"Interaction of YB-1 with human immunodeficiency virus type 1 Tat and TAR RNA modulates viral promoter activity","volume":"80","author":"Ansari","year":"1999","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.drudis.2019.03.013_bib0480","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0200080","article-title":"Y-box-binding protein 1 supports the early and late steps of HIV replication","volume":"13","author":"Weydert","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2019.03.013_bib0485","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/1871526518666180327124412","article-title":"Implication of B23\/nucleophosmin in viral infections, potential uses of B23\/NPM1 inhibitors as antiviral therapy","volume":"19","author":"Lobaina","year":"2019","journal-title":"Infect. Disord. Drug Targets"},{"key":"10.1016\/j.drudis.2019.03.013_bib0490","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1021\/acs.accounts.7b00154","article-title":"Natural seminal amyloids as targets for development of synthetic inhibitors of HIV transmission","volume":"50","author":"Sheik","year":"2017","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.drudis.2019.03.013_bib0495","doi-asserted-by":"crossref","first-page":"9033","DOI":"10.1073\/pnas.0811827106","article-title":"The main green tea polyphenol epigallocatechin-3-gallate counteracts semen-mediated enhancement of HIV infection","volume":"106","author":"Hauber","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2019.03.013_bib0500","doi-asserted-by":"crossref","first-page":"35488","DOI":"10.1074\/jbc.M110.163659","article-title":"Amyloid-binding small molecules efficiently block SEVI (semen-derived enhancer of virus infection)- and semen-mediated enhancement of HIV-1 infection","volume":"285","author":"Olsen","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2019.03.013_bib0505","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1074\/jbc.M109.066167","article-title":"Aminoquinoline surfen inhibits the action of SEVI (semen-derived enhancer of viral infection)","volume":"285","author":"Roan","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2019.03.013_bib0510","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.bbrc.2016.12.013","article-title":"A fluorescence-based high-throughput assay to identify inhibitors of tyrosylprotein sulfotransferase activity","volume":"482","author":"Zhou","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.drudis.2019.03.013_bib0515","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1042\/BCJ20180266","article-title":"New tools for evaluating protein tyrosine sulfation: tyrosylprotein sulfotransferases (TPSTs) are novel targets for RAF protein kinase inhibitors","volume":"475","author":"Byrne","year":"2018","journal-title":"Biochem. J."},{"key":"10.1016\/j.drudis.2019.03.013_bib0520","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nsmb964","article-title":"A peptide inhibitor of HIV-1 assembly in vitro","volume":"12","author":"Sticht","year":"2005","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.drudis.2019.03.013_bib0525","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1128\/AAC.02574-15","article-title":"Ebselen, a small-molecule capsid inhibitor of HIV-1 replication","volume":"60","author":"Thenin-Houssier","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drudis.2019.03.013_bib0530","doi-asserted-by":"crossref","first-page":"10593","DOI":"10.1039\/C6OB01731B","article-title":"Synthesis of HIV-1 capsid protein assembly inhibitor (CAP-1) and its analogues based on a biomass approach","volume":"14","author":"Romashov","year":"2016","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.drudis.2019.03.013_bib0535","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1021\/np50104a008","article-title":"Anti-AIDS agents, 11. Betulinic acid and platanic acid as anti-HIV principles from Syzigium claviflorum, and the anti-HIV activity of structurally related triterpenoids","volume":"57","author":"Fujioka","year":"1994","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.drudis.2019.03.013_bib0540","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/cbdd.13175","article-title":"1,2,3,4-Tetrahydroisoquinolines as inhibitors of HIV-1 integrase and human LEDGF\/p75 interaction","volume":"91","author":"George","year":"2018","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.drudis.2019.03.013_bib0545","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.ejmech.2016.10.045","article-title":"Discovery of novel 3-hydroxypicolinamides as selective inhibitors of HIV-1 integrase-LEDGF\/p75 interaction","volume":"125","author":"Zhang","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.drudis.2019.03.013_bib0550","doi-asserted-by":"crossref","first-page":"4748","DOI":"10.1016\/j.bmcl.2016.08.037","article-title":"Indole-based allosteric inhibitors of HIV-1 integrase","volume":"26","author":"Patel","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.drudis.2019.03.013_bib0555","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1016\/j.ddtec.2013.07.002","article-title":"Small molecule inhibitors of the HIV-1 virulence factor","volume":"10","author":"Smithgall","year":"2013","journal-title":"Nef. Drug Discov. Today Technol."}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644618305270?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644618305270?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:39:20Z","timestamp":1761223160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644618305270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":111,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S1359644618305270"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2019.03.013","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New targets for HIV drug discovery","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2019.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}